Dark Blue Therapeutics

Dark Blue Therapeutics, a biotech discovery and development spin-out from the University of Oxford, is pioneering the next generation of precision oncology. The company leverages collaborations with world-class academic experts to uncover novel vulnerabilities and dependencies in cancer. Its experienced management team brings decades of pharmaceutical R&D expertise across the entire development spectrum, advancing precision medicine approaches applicable to a wide range of cancer mechanisms. Dark Blue focuses on the most valuable drug targets, integrating the most effective chemical technologies to build a pipeline of transformative first-in-class drugs. The lead program is an MLLT1/3 degrader, currently in development as a monotherapy and combination therapy for patients with acute myeloid leukemia (AML) and solid tumors, alongside a new discovery program targeting ADAR1 inhibition. Dark Blue’s key shareholders include Oxford Science Enterprises, Bristol-Myers Squibb, and Evotec.